icon

Amarin (AMRN) shares dropped six percent on Thursday, closing  below nine bucks...

Read more

The high-flying shares of Ampio Pharmaceuticals (AMPE) about hit their 52-week high of $9.21 just weeks after trading for under five bucks as multiple positive developments provided the needed catalysts to spark a share price run.

During that time, however, the short interest grew, and after a ten pe...

Read more

BioDelivery Sciences (BDSI) announced this week that the primary endpoint for its recently-completed Phase III BEMA Bup trial was missed, although some results were encouraging enough to spur the company to look towards conducting another efficacy trial that will run approximately nine months from i...

Read more

Siga's (SIGA) dropping share price over the months since being awarded a government contract for its smallpox antiviral ST-246 is evidence enough that many in the market predicted a negative decision from the judge that would rule on the legal battle with PharmAthene (PIP) that revolved around a mer...

Read more

Some health care stocks to watch this week:

MNKD: Closing a week that saw many stocks get crushed, Mannkind (MNKD) made headlines on Friday by finishing the day up 18% on news that the company plans to sell senior secured discount notes due in 2017. The deal will raise about $370 million and position...

Read more

Cytosorbents (CTSO) shares have been on a roller coaster ride over the past year while moving from a relative unknown on the bulletin boards to becoming a commercial stage company with a potentially breakthrough product on the European market.

Surprising approval news in Europe - and I say surprising...

Read more

Even on a day when the DOW drops 300 points at the open, there's sure to be a good news story somewhere.

Although down on Thursday morning, shares of Human Genome Sciences (HGSI) were up 12% on Wednesday following an announcement that sales of the company's recently-approved lupus drug Benlysta excee...

Read more

Although Generex (GNBT.ob) continues to trade with a share price of a dime, the recent news developments continue to give investors a look at the future potential of the company, including the soon-to-be spun off subsidiary Antigen Express (AE).

Since AE-37 was labeled as the center piece of the futu...

Read more

Spectrum Pharmaceuticals (SPPI) has enjoyed a stellar 52-week period, significantly increasing its revenue stream while the share price more than doubled.

Milestone news was also announced earlier in the year when the FDA approved Spectrum's Fusilev for the treatment of colorectal cancer, and anothe...

Read more

Agenus Inc. (AGEN) is primarily known for its pipeline cancer immunothearpy product Prophage and its potential to reach market as a treatment for glioma, but recent headlines have been highlighting another of the company's strengths, its vaccine adjuvant, QS-21.

The potential of QS-21 has long been ...

Read more

A string of recent headlines from Generex (OTC: GNBT) and Antigen Express (AE) has looked to reignite some spark into the share price, but thus far the campaign of positive updates has failed to make a difference.

While Generex's buccal insulin spray Oral-lyn and Antigen Express's cancer vaccine coul...

Read more

Stock Briefs: SPPI, AGEN

Posted by Posted by VFC on Sep 20, 2011

SPPI: Spectrum Pharmaceuticals (SPPI) has enjoyed a stellar 52-week period, significantly increasing its revenue stream while the share price more than doubled.

Milestone news was also announced earlier in the year when the FDA approved Spectrum's Fusilev for the treatment of colorectal cancer, and ...

Read more

When Capstone Turbine (CPST) quickly soared past the two dollar mark earlier this year on a run of large orders and a presidential mention, many shareholders thought that this time the run would be for real, and the stock would never look back towards the days it spent trading for under a buck.

That ...

Read more

Shares of Keryx Pharmaceuticals (KERX) had slipped during the latest round of market turmoil before rebounding back to the four dollar mark as uneasy investors jumped back in. KERX has reached highs of over six dollars in the past couple of years as the company's primary pipeline products, Zerenex f...

Read more

Shares of Cel-Sci (CVM) are still trading for below forty cents, but even as interest in the stock is low right now, CVM could quickly turn into a mid to long term keeper should the ongoing global Phase III Multikine trial prove successful.

The trial started at the close of last year and has since sp...

Read more

Last month Generex (GNBT.ob) provided investors with an update on the Phase II breast cancer vaccine AE-37, which is being developed by subsidiary Antigen Express. Although that update followed one that was also encouraging regarding the insulin spray Oral-lyn, potential investors were unimpressed a...

Read more

Stocks and Stories to watch this week:

DNDN: As the aftermath from the Dendreon fallout continues to play out in the healthcare and cancer immunotherapy sectors, the company recently announced a round of mass layoffs resulting from the failure of Provenge to sell at rates previously expected by the c...

Read more

Ampio Pharmaceuticals (AMPE) recorded another solid week last week, breaking through the nine dollar price-per-share barrier while continuing an uptrend that started in mid August. The uptrend has been supported by a string of encouraging news releases over the past month that may be attracting new ...

Read more

Immunocellular Therapeutics (IMUC.ob) issued an update on Wednesday of its Phase II trial for ICT-107, a dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of the highly-aggressive form of brain cancer, glioblastoma multiforme (GBM).

The already-complet...

Read more

Having been labeled as a 'Stock to Watch' this week because of the company's upcoming participation in the 'International Congress of the German Sepsis Society' n Weimar, Germany, Cytosorbents made headlines again on Wednesday morning - the day the conference is to start - by announcing the secondar...

Read more

Already noted as a 'Stock to Watch' this week, keep an eye on Dendreon Corp. (DNDN) over the short term as the company issued an after-hours press release on Wednesday announcing a 4:30 PM Thursday conference call where management will "provide a structural and business update on the company."

It's t...

Read more

BioDelivery Sciences (BDSI) has started making some noise again after a year of a relative flatline as discussions with the FDA were taking place to finalize the REMS issues regarding Onsolis in the United States.

A few weeks ago the company announced that Onsolis would be launched on the Canadian m...

Read more

AMRN: The volatile trading of Amarin Corporation (AMRN) should continue during the opening weeks of September as the company is expected to file for approval with the FDA for AMR-101 in the treatment of high triglycerides.

Amarin rose to nearly twenty bucks after positive results from a pair of Phase...

Read more

Ever since the market rumble that sent shares of Dendreon (DNDN) dropping after the company pulled its year-end sales guidance for Provenge, other stocks in the sector followed suit and have been trading for significantly lower prices than were available just months ago.

Some of those dropping stocks...

Read more